Neurocrine Biosciences, Inc. EPS (Earnings per Share) 2009–2025
Neurocrine Biosciences, Inc. reported $4.67 of earnings per share for fiscal 2025. That was 41.9% higher than fiscal 2024. Compared with fiscal 2020, the change was +12.3%.
| Fiscal year | EPS (Earnings per Share) | Change (YoY) |
|---|---|---|
| FY 2025 | $4.67 | +41.9% |
| FY 2024 | $3.29 | +33.2% |
| FY 2023 | $2.47 | +58.3% |
| FY 2022 | $1.56 | +69.6% |
| FY 2021 | $0.92 | -77.9% |
| FY 2020 | $4.16 | +966.7% |
| FY 2019 | $0.39 | +77.3% |
| FY 2018 | $0.22 | +113.6% |
| FY 2017 | $-1.62 | +0.6% |
| FY 2016 | $-1.63 | -55.2% |
| FY 2015 | $-1.05 | -29.6% |
| FY 2014 | $-0.81 | -17.4% |
| FY 2013 | $-0.69 | -962.5% |
| FY 2012 | $0.08 | -88.1% |
| FY 2011 | $0.67 | +546.7% |
| FY 2010 | $-0.15 | +88.5% |
| FY 2009 | $-1.30 | — |
Source: Neurocrine Biosciences, Inc. SEC filings — income statement (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open NBIX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Neurocrine Biosciences, Inc. reported $4.67 of earnings per share for fiscal 2025. That was 41.9% higher than fiscal 2024. Compared with fiscal 2020, the change was +12.3%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Neurocrine Biosciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeNeurocrine Biosciences, Inc. — frequently asked questions
What is Neurocrine Biosciences, Inc.'s earnings per share?
Neurocrine Biosciences, Inc. (NBIX) reported earnings per share of $4.67 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Neurocrine Biosciences, Inc.'s official SEC filings (income statement (10-K), split-adjusted), refreshed nightly. Not investment advice.